Show the Working

Right to See a GP Within Seven Days (or 24 Hours Urgent)

Liberal Democrat · what the evidence says

An independent, source-checked look at Liberal Democrat’s policy “Right to See a GP Within Seven Days (or 24 Hours Urgent)” — what it would actually do across the things that affect your life. Every claim below quotes the source behind it. How this works.

Public finances & the next generation — Hurts

moderate · low confidence

This policy commits to substantial new spending — including 8,000 more GPs and a named-GP guarantee estimated at £1 billion a year — with no stated funding source in the policy text. Without a credible funding plan, the near-term debt path worsens, though the full fiscal scale remains unquantified.

The evidence

Biggest unknown: Whether the full package is costed and funded — no overall fiscal estimate is provided in the policy text or the evidence, making the net debt-path effect impossible to judge precisely.

Our reading: The policy makes several substantial spending commitments — 8,000 new FTE GPs, a named-GP guarantee, a new booking system, an expanded pharmacist prescribing programme, and a rural surgeries fund. The only independently cited cost estimate covers one element (named GPs for 70+ and those with long-term conditions), projected at £1 billion per year. No overall fiscal envelope is given in the policy text, and the evidence confirms no full costing has been independently published. The absence of a stated funding mechanism is the central fiscal problem: a package of this scale amounts to unfunded spending under current evidence. NHS spending is already growing below its historic average and is crowding out other public services; adding uncosted commitments worsens the near-term debt path. The direction is therefore 'worsens' on a 'spending without stated funding' basis. The magnitude is 'moderate' rather than 'major' because some elements (task-shifting to pharmacists) are ongoing NHS policy with incremental costs, retention measures may be cheaper than new recruitment, and productivity gains from reduced bureaucracy could partially offset costs — though none of these are quantified in the provided evidence. Confidence is 'low' because no full independent fiscal score is available in the evidence; the verdict could shift to 'negligible' or 'mixed' if a credible funding plan were demonstrated. Near-term, the unfunded commitment worsens the debt path; long-term, healthier population outcomes could improve fiscal sustainability, but this productive-investment case is not evidenced at the required level of specificity in the provided units.

Healthcare — Mixed picture

moderate · moderate confidence

This policy targets a real and serious problem — GP access is genuinely poor and getting worse — and proposes concrete mechanisms like 8,000 more GPs and task-shifting to pharmacists. But delivering 8,000 extra FTE GPs is extremely hard given current workforce trends, and a legal right without the staff to back it could create pressure without capacity.

The evidence

Biggest unknown: Whether 8,000 additional FTE GPs can realistically be recruited and retained given chronic workforce decline, high attrition intentions, and the structural factors that have caused FTE to fall even as headcount rose.

Our reading: The policy targets a demonstrably serious problem. FTE GP numbers have fallen while the patient list has grown by 6.7 million, pushing the patient-to-GP ratio up by 13.5%. Five million appointments waited over 14 days in 2022. The baseline is bad and deteriorating. The policy's most important lever — 8,000 additional FTE GPs — is also its most uncertain. The workforce data reveals a structural problem: past licensing of more GPs has not translated into FTE gains (one FTE gained per five licensed). With 71% of GPs already reporting extreme stress and 39% considering leaving, retention is the crux. If the retention half of the 8,000 target succeeds, it directly addresses the pipeline leak; if not, the recruitment half alone is unlikely to deliver net FTE gains at scale. Task-shifting to pharmacists, nurse practitioners, and paramedics is a sound and evidence-supported direction — pharmacist prescribing has grown substantially and the CQC endorses the model. This element is deliverable in a shorter timeframe and provides genuine if partial relief. The named-GP commitment is expensive (£1bn/yr), slow (4+ years), and has weak near-term evidence of impact on continuity metrics. The 24/7 booking system builds on already near-universal online access and the BMA warns it could backfire without workforce to match. Overall: the policy's goal is correct and its best mechanisms (task-shifting, retention incentives, rural fund) are plausibly beneficial. But the legal 'right' without guaranteed staffing capacity is a commitment that could be largely symbolic in the short term. The direction is mixed: genuine upside if the workforce targets are even partially met; risk of a mandate-without-capacity trap if they are not. The time horizon is long-term because the GP pipeline takes years and the named-GP element alone would take at least four years.